From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O -GalNAc Glycosylation in Cancer
Chemical Reviews · 2026
DOI: 10.1021/acs.chemrev.5c00901 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemical Reviews, 2026. Verfasst von Mikkel Koed Møller Aasted und 5 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Center for Glycocalyx Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3B, 2200Copenhagen, D…. Hauptthemen laut MEDLINE: Neoplasms, Polysaccharides, Precision Medicine, N-Acetylgalactosaminyltransferases. Die Arbeit nennt 604 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Molecular Biology Organization, H2020 European Research Council, HORIZON EUROPE Marie Sklodowska-Curie Actions.
Abstract (Originalsprache)
Aberrant O-glycosylation is a prominent feature of cancer and contributes directly to multiple hallmarks of malignant transformation. Cancer-associated O-glycans include both truncated structures that are unique to mucin-type O-glycosylation and more elongated terminal motifs that function as ligands for glycan-binding proteins. Instead of representing a simple binary change from elongated to truncated structures, it is increasingly understood that these glycans decorate the cancer cell surface with a heterogeneous pattern of truncated, elongated, capped, and partially processed glycoforms, which coexist even on individual proteins and within the tumor glycocalyx. Functionally, truncated aberrant O-GalNAc glycans, such as Tn, STn, and T perturb epithelial differentiation, barrier integrity, signaling, and immunosuppression through interactions with glycan binding receptors, such as Siglecs and MGL. In addition, more elongated O-glycans, including Lewis antigens, interact with selectins promoting metastasis and cellular trafficking. Moreover, individual GalNAc-transferase isoenzymes, governing site-specific O-glycosylation, are emerging as context-dependent regulators of oncogenic processes through glycosylation of selected proteins. These observations establish cancer-associated O-glycans as context-dependent molecular drivers of tumor progression and promising therapeutic entry points. In this review, we discuss the expression, regulation, and functions of cancer-associated O-glycans, their roles in glycan-binding protein biology, and emerging therapeutic strategies that may enable a new generation of glycan-directed precision treatments in oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Copenhagen Center for Glycocalyx Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3B, 2200Copenhagen, Denmark.
- Department of Biotechnology, Faculty of Science, Mahidol University, 272 Rama VI Road, Ratchathewi District, Bangkok10400, Thailand.
- Brigham and Women's Hospital , Department of Pathology, 75 Francis Street, Boston, Massachusetts02115, United States.
ORCID-Profile: Hans H Wandall
Förderung
- European Molecular Biology Organization
- H2020 European Research Council
- HORIZON EUROPE Marie Sklodowska-Curie Actions
- HORIZON EUROPE European Innovation Council
- Danmarks Grundforskningsfond
- Lundbeck Foundation
- Mahidol University
- Danmarks Frie Forskningsfond
Zitieren
APA
Aasted, M. K. M., Jaroentomeechai, T., Dabelsteen, S., Joshi, H., Stowell, S. R., & Wandall, H. H. (2026). From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O -GalNAc Glycosylation in Cancer. Chemical Reviews. https://doi.org/10.1021/acs.chemrev.5c00901
Vancouver
Aasted MKM, Jaroentomeechai T, Dabelsteen S, Joshi H, Stowell SR, Wandall HH. From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O -GalNAc Glycosylation in Cancer. Chemical Reviews. 2026. doi:10.1021/acs.chemrev.5c00901
BibTeX
@article{Aasted2026,
author = {Aasted, Mikkel Koed Møller and Jaroentomeechai, Thapakorn and Dabelsteen, Sally and Joshi, Hiren and Stowell, Sean R and Wandall, Hans H},
title = {From Glycocode to Precision Oncology: Therapeutic Strategies Targeting Aberrant O -GalNAc Glycosylation in Cancer},
journal = {Chemical Reviews},
year = {2026},
doi = {10.1021/acs.chemrev.5c00901}
}
EUVIMED